Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

All news

Show

From To
UK: Foreigner's health issues insufficient to halt deportation

In an landmark decision, the UK Appeal Court decision has ruled that the deportation of a Nigerian man with sickle cell disease would not be a contravention of the European Convention on Human Rights.

Published
11 July 2019
From
Legalbrief
In New York City, PrEP on Demand Is Now on the Menu for Men Who Have Sex With Men

For a long time, the most common way to describe pre-exposure prophylaxis (PrEP) was that it is a daily pill taken to prevent acquiring HIV. But now, New York City is tackling what might be a barrier to PrEP uptake with its new on-demand PrEP initiative.

Published
11 July 2019
From
The Body Pro
Insurance Will Soon Cover HIV Prevention, But Many People Who Need it Still Won't Have Access

When Corey Walsh began using the drug Truvada, the pills were free but the quarterly lab tests and doctors' visits cost almost $400.

Published
11 July 2019
From
Vice
ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice

The long-acting injectable regimen has been granted Priority Review status by the FDA, with a target approval date set for December 29, 2019

Published
11 July 2019
From
ViiV Healthcare press release
Analysis Backs New Tenofovir’s Kidney Safety Over Old Version

Researchers compared data on more than 9,000 people with HIV who took either version of tenofovir.

Published
11 July 2019
From
POZ
GSK touts new Dovato switching data. Is it enough to shake Gilead's HIV lead?

GlaxoSmithKline’s ViiV Healthcare already boasts an approval for Dovato, a two-drug HIV regimen, in newly diagnosed patients. And it just added some new data that aims to at least draw level with market leader Gilead in already-treated patients.

Published
11 July 2019
From
FiercePharma
UK: Take home naloxone is not reaching those who most need it

Naloxone is key is to addressing the current opioid crisis, but poor systemic distribution means it isn’t saving the lives it should, says Zoe Carre

Published
11 July 2019
From
The BMJ
"Tiger Mandingo,” Who Got 30 Years For Not Telling Sex Partners He Had HIV, Is Free 25 Years Early

Michael Johnson, who was sentenced to an unprecedented 30.5 years for failing to disclose his HIV status to his sexual partners, was released today, 25 years early, after an appeals court condemned his original trial as “fundamentally unfair.” In a racially and sexually charged trial, he had received a longer sentence than many murderers do.

Published
11 July 2019
From
BuzzFeed
Lyndra Therapeutics and Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics

Lyndra Therapeutics, the company making daily pills a thing of the past, has announced a partnership with Gilead Sciences, Inc. to develop and commercialize ultra-long-acting oral HIV therapies. Gilead will have exclusive rights to Lyndra’s therapeutics platform for ultra-long-acting formulations related to HIV.

Published
10 July 2019
From
Lyndra Therapeutics press release
Louisiana HIV Rates Are the Lowest in a Decade

Doctors attribute the drop to increased testing and U=U.

Published
10 July 2019
From
POZ

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.